The Journal of allergy and clinical immunology
September 5, 2026 · via Europe PMC
Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, +11 more, Lindsley A.
AI summary — for doctors, generated from the abstract only
This review synthesizes lessons from clinical trials of TSLP inhibition (an epithelial cytokine pathway) across multiple type-2-driven diseases, noting tezepelumab is currently the only approved anti-TSLP therapy while over ten additional TSLP-targeting agents are in clinical development for conditions including asthma, nasal polyps, COPD, allergic rhinitis, atopic dermatitis, and chronic urticaria.
What was studied
A narrative review examining preclinical and clinical evidence regarding thymic stromal lymphopoietin (TSLP) as a therapeutic target across multiple type-2 immune-mediated epithelial-driven diseases, summarizing lessons learned from tezepelumab trials and the broader TSLP-targeting drug development landscape.
Key findings
- TSLP is an epithelial cytokine that regulates both type-2 and non-type-2 inflammation by activating dendritic cells and promoting release of IL-4, IL-5, and IL-13.
- Tezepelumab, a monoclonal antibody that selectively blocks TSLP from interacting with its receptor, is currently the only approved anti-TSLP therapy.
- The review examines clinical trial evidence for TSLP-driven inflammation across asthma, chronic rhinosinusitis with nasal polyps, COPD, allergic rhinitis, atopic dermatitis, and chronic spontaneous urticaria.
- At least eleven other TSLP-targeting agents (including ecleralimab, SHR-1905, bosakitug, verekitug, sunakiment, TAVO101, ocankitug, HBM9378, MG-ZG122, GB-0895, and solrikitug) are in clinical development.
Clinical relevance
The findings suggest TSLP blockade represents a clinically validated therapeutic approach across a broad range of type-2-driven epithelial diseases beyond asthma (its first approved indication), which is relevant to clinicians anticipating an expanding array of TSLP-targeted treatment options for conditions like nasal polyps, COPD, atopic dermatitis, and chronic urticaria as additional agents complete clinical development.
Who should care
Limitations
This is a narrative review rather than a systematic review or new clinical trial; it does not report specific efficacy statistics for each disease indication or for the agents still in development, several of which have not yet completed clinical trials.
TSLP blockade is proving to be an effective therapeutic strategy across multiple type-2 inflammatory diseases beyond asthma, with tezepelumab currently the only approved agent while over a dozen additional TSLP-targeting drugs are in development.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Type 2 (T2) immune-mediated epithelial-driven diseases are characterized by dysregulated immune responses at epithelial barrier surfaces. A key mediator of these diseases is thymic stromal lymphopoietin (TSLP), an epithelial cytokine that acts as a regulator of both T2 and non-T2 inflammation. TSLP activates dendritic cells and other immune cells, promoting the release of proinflammatory cytokines, including IL-4, IL-5, and IL-13. Given its central role in initiating and amplifying T2 inflammation, TSLP has emerged as a promising therapeutic target in multiple epithelial-driven inflammatory diseases. Tezepelumab is a human monoclonal antibody that selectively blocks TSLP from interacting with its receptor complex, thereby interrupting this inflammatory cascade, and its study in various disease states has clarified the clinical importance of TSLP-driven inflammation. In this review, we examine preclinical and clinical evidence and enumerate the lessons learned to date regarding the role of TSLP in sustaining select T2 inflammatory diseases, specifically asthma, chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, allergic rhinitis, atopic dermatitis, and chronic spontaneous urticaria. Tezepelumab is currently the only approved anti-TSLP therapy. Other TSLP-targeting agents, including ecleralimab, SHR-1905, bosakitug, verekitug, sunakiment, TAVO101, ocankitug, HBM9378, MG-ZG122, GB-0895, and solrikitug, are in clinical development.
DOI
10.1016/j.jaci.2026.08.022
PMID
42697279
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed